Sign in

Delix

$100M · November 2026 · Biotech & pharma · North America

What it sells

Delix Therapeutics develops neuroplastogens, a class of compounds intended as safe, fast-acting and long-lasting treatments for brain health conditions. Lead candidate Zalsupindole is entering Phase II.

Funding history and coverage

Round dateStageAmountInvestorsSource
2026-11-09—$100MJ&Jnews.google.com

Profiles summarize public reporting and company websites. Business-model notes are MaxBC's reading of that material, not confirmed facts; unknowns are left blank rather than guessed. Updated 2026-11-10.

More startups in Biotech & pharma

  1. Kardi Ai

    Kardi Ai is a non-invasive, reusable single-lead ECG medical device for adults that records and analyses the heart's electrical activity, for home or clinical use, detecting…

    Series A · €5.3M · 2026-11-11Biotech & pharmaEurope

  2. Switchpoint Bio

    Switchpoint Bio combines blood-based epigenomics (DNA methylation) and AI to produce decision-grade evidence for drug development: biomarker discovery, patient stratification and…

    $5.3M · 2026-11-11Biotech & pharmaEurope

  3. SRTD Biotech

    Cell-selective mRNA therapeutics: seRNA constructs are delivered inactive and switch on only when they detect a disease-specific RNA inside the target cell, found by an AI…

    Seed · €31.5M · 2026-11-10Biotech & pharmaEurope

  4. Lucidome Bio

    Lucidome Bio is developing a vaccine that triggers antibodies against methanogens in the rumen to cut methane emissions from cattle and other ruminant livestock, including…

    $9M · 2026-11-10Biotech & pharmaAsia

  5. Efferon

    Efferon makes CE-marked multimodal hemoadsorption devices (Efferon LPS for adults, Efferon NEO for children) that remove endotoxin and cytokines from the blood to treat sepsis…

    Seed · €4.3M · 2026-11-10Biotech & pharmaEurope

  6. Oyster Therapeutics

    Develops targeted protein degrader therapeutics using its SELFTAC platform, where two small molecules cross biological barriers and self-assemble into a full degrader. First…

    Series A-2 · $60M · 2026-11-10Biotech & pharmaOther regions

All startups in this market →